Prosensa, GSK Expand DMD Alliance

Prosensa has initiated two further programs under its alliance with GlaxoSmithKline covering novel RNA-based treatments for Duchenne Muscular Dystrophy (DMD). The two new programs are included under the companies existing alliance and includes the development of four compounds that target different subpopulations of patients suffering from DMD. GSK has made two initiation payments to Prosensa and Prosensa is eligible for further pre-option milestone payments based on research progress.

GSK has an option to select two of these additional four compounds for later-stage development and commercialization. Prosensa will retain certain European commercialization rights along with GSK for the two compounds selected by GSK. Prosensa will retain full commercialization rights for the two compounds not selected by GSK.

“The expansion of our DMD portfolio with four additional compounds is a great step forward in our efforts to develop safe and effective treatments for this severely debilitating disease and to help as many patients as possible,” said Hans Schikan, chief executive officer of Prosensa. “Thanks to the successful progress in our existing program with GSK, we are now able to extend our productive collaboration with these four further compounds.”